|Articles|October 1, 2017

PE 2017 AAM Statement

External Link - Pharm-Exec-2017-statement.pdf

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Pharmaceutical Executive Daily: Executive Order Reduces Childhood Vaccine Recommendations

ByNicholas Jacobus

August 11th 2026

U.S. Rare Disease Biotech Investing Rises After FDA’s PRV Program Renewal: Report

ByNicholas Jacobus

August 11th 2026

What 40 Conversations About a Pandemic Taught Me About How Pharma Communicates

ByKishan Rees, M.D.

August 11th 2026

Executive Order Cuts Recommended Childhood Vaccines Down to 11: Report

ByNicholas Jacobus

August 11th 2026

BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies

ByNicholas Jacobus

August 11th 2026

PE 2017 AAM Statement

Related Content

Pharmaceutical Executive Daily: Executive Order Reduces Childhood Vaccine Recommendations

U.S. Rare Disease Biotech Investing Rises After FDA’s PRV Program Renewal: Report

What 40 Conversations About a Pandemic Taught Me About How Pharma Communicates

Executive Order Cuts Recommended Childhood Vaccines Down to 11: Report

BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies

Trending on PharmExec

Everything You Need to Know About the AstraZeneca–Bristol Myers Squibb Merger Rumors

Executive Order Cuts Recommended Childhood Vaccines Down to 11: Report

BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies

Pharmaceutical Executive Daily: Jazz Acquires Actio Bioscience

The Science of Targeting Multiple Immune Components in ITP: Q&A with Dr. Srikanth Nagalla